Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gert Van Assche

Showing results (191-200 of 287) with videos related to

Pageof 29
Sort By:
The American Journal of Gastroenterology|June 9, 2015
Corrigendum: Oral Prolonged Release Beclomethasone Dipropionate and Prednisone in the Treatment of Active Ulcerative Colitis: Results From a Double-Blind, Randomized, Parallel Group StudyGert Van Assche, Francesco Manguso, Marco Zibellini, et al.
Clinical Immunology (Orlando, Fla.)|August 17, 2004
Functional expression of 4-1BB (CD137) in the inflammatory tissue in Crohn's diseasePhilippe Maerten, Karel Geboes, Gert De Hertogh, et al.
International Immunopharmacology|June 9, 2004
Inhibition of glycolipid biosynthesis by N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin protects against the inflammatory response in hapten-induced colitisChong Shen, Dominique Bullens, Ahmad Kasran, et al.
Inflammatory Intestinal Diseases|December 14, 2020
A Multicentre, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of the S1P Receptor Agonist KRP203 in Patients with Moderately Active Refractory Ulcerative ColitisHeinfried H Radeke, Jürgen Stein, Gert Van Assche, et al.
Inflammatory Bowel Diseases|February 16, 2010
Effects of T cell-induced colonic inflammation on epithelial barrier functionPeter Suenaert, Philippe Maerten, Gert Van Assche, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 19, 2015
Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative ColitisKonstantinos Papamichael, Thomas Van Stappen, Niels Vande Casteele, et al.
Inflammatory Bowel Diseases|February 2, 2016
Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's DiseaseEran Zittan, Orlaith B Kelly, Richard Kirsch, et al.
Gastroenterology|October 9, 2007
A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitisScott Plevy, Bruce Salzberg, Gert Van Assche, et al.
The American Journal of Gastroenterology|April 15, 2015
Oral prolonged release beclomethasone dipropionate and prednisone in the treatment of active ulcerative colitis: results from a double-blind, randomized, parallel group studyGert Van Assche, Francesco Manguso, Marco Zibellini, et al.
Gut|May 22, 2016
Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBDJoão Sabino, Sara Vieira-Silva, Kathleen Machiels, et al.
Pageof 29

Showing results (191-200 of 287) with videos related to

Sort By:
Pageof 29
The American Journal of Gastroenterology|June 9, 2015
Corrigendum: Oral Prolonged Release Beclomethasone Dipropionate and Prednisone in the Treatment of Active Ulcerative Colitis: Results From a Double-Blind, Randomized, Parallel Group StudyGert Van Assche, Francesco Manguso, Marco Zibellini, et al.
Clinical Immunology (Orlando, Fla.)|August 17, 2004
Functional expression of 4-1BB (CD137) in the inflammatory tissue in Crohn's diseasePhilippe Maerten, Karel Geboes, Gert De Hertogh, et al.
International Immunopharmacology|June 9, 2004
Inhibition of glycolipid biosynthesis by N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin protects against the inflammatory response in hapten-induced colitisChong Shen, Dominique Bullens, Ahmad Kasran, et al.
Inflammatory Intestinal Diseases|December 14, 2020
A Multicentre, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of the S1P Receptor Agonist KRP203 in Patients with Moderately Active Refractory Ulcerative ColitisHeinfried H Radeke, Jürgen Stein, Gert Van Assche, et al.
Inflammatory Bowel Diseases|February 16, 2010
Effects of T cell-induced colonic inflammation on epithelial barrier functionPeter Suenaert, Philippe Maerten, Gert Van Assche, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 19, 2015
Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative ColitisKonstantinos Papamichael, Thomas Van Stappen, Niels Vande Casteele, et al.
Inflammatory Bowel Diseases|February 2, 2016
Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's DiseaseEran Zittan, Orlaith B Kelly, Richard Kirsch, et al.
Gastroenterology|October 9, 2007
A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitisScott Plevy, Bruce Salzberg, Gert Van Assche, et al.
The American Journal of Gastroenterology|April 15, 2015
Oral prolonged release beclomethasone dipropionate and prednisone in the treatment of active ulcerative colitis: results from a double-blind, randomized, parallel group studyGert Van Assche, Francesco Manguso, Marco Zibellini, et al.
Gut|May 22, 2016
Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBDJoão Sabino, Sara Vieira-Silva, Kathleen Machiels, et al.
Pageof 29